Clinical and microbiological profile of health care associated pneumonia in patients with chronic renal disease referred to a tertiary care hospital- a prospective study

C. Mohan Rao, Saswat Subhankar, Aswini Prasad Patnaik, Debee Prasad Dash


Background: Healthcare associated pneumonia (HCAP) is a public health problem in the era of home care of chronic illness including chronic renal disease. They have greater burden of comorbidities, immune suppression and impaired mobility. Aim of the Study: To characterise the clinical, radiological and microbiological profile of health care associated pneumonia in chronic renal disease cases including its resistance pattern and outcome in the study population. Materials and Methods: This prospective study was conducted among patients with chronic kidney disease (CKD) who had been treated in multiple hospitals across Odisha. They were subjected to history taking, clinical examination, laboratory and radiological investigations. Sputum or endotracheal tube culture were sent for gram stain and aerobic culture. All the categorical parameters were compared using Fisher’s exact test. Continuous parameters were compared using independent t-test. All the statistical analysis was carried out using the software Stata 15.1. A p-value less than 0.05 was considered significant. Results and Discussion: 58 patients with an underlying chronic kidney disease were included. 54 (93.1%%) patients survived while 4 (6.9%) died. The mean age, total leucocyte count and serum urea levels were higher among patients who died in comparison to the survivors (p= 0.95, 0.334 and 0.386 respectively). Klebsiella spp (12.07%), and Acinetobacter (8.6%) were most commonly isolated. Multi-drug resistance (MDR) and extensive drug resistance (XDR) were encountered among these organisms. Death was more commonly associated in patients ≥60yrs (p= 1), TLC ≥ 11000 cells/mm3 (p= 0.0091), serum creatinine ≥ 3mg/dl (p= 0.329) and radiological involvement of ≥ 3zones (p= 1). Conclusion: CKD is an important contributor in HCAP. Data from different institutions to corroborate our findings regarding antibiotic resistance pattern of the microbes in HCAP cases is recommended.

Full Text:



Hill N, Fatoba S, Oke J, Hirst J, O’Callaghan C, Lasserson D et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(7): e0158765.

Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. The Lancet Global Health. 2016;4(5): e307-e319.

Guidelines for the Management of Adults with Hospital-acquired,Ventilator-associated, and Healthcare - associated Pneumonia. American Journal of Respiratory and Critical Care Medicine. 2005;171 (4): 388-416.

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. Clinical Infectious Diseases. 2011; 52 (suppl_5): S397-S428.

Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013; 34:1–14. doi: 10.1086/668770.

Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and Factors Associated with Early Failure in Hospitalized Patients with Community-Acquired Pneumonia. Archives of Internal Medicine. 2004;164(5):502.

Slinin Y, Foley R, Collins A. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney International. 2006;70 (6): 1135-1141.

Guo H, Liu J, Collins A, Foley R. Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrology Dialysis Transplantation. 2007;23 (2): 680-686.

Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N et al. Health-Care-Associated Pneumonia Among Hospitalized Patients in a Japanese Community Hospital. Chest. 2009;135(3):633-640.

Carratalà J, Mykietiuk A, Fernández-Sabé N, et al. Health Care–Associated Pneumonia Requiring Hospital Admission: Epidemiology, Antibiotic Therapy, and Clinical Outcomes. Arch Intern Med. 2007;167(13): 1393–1399. doi:10.1001/archinte.167.13.1393

Micek S, Kollef K, Reichley R, Roubinian N, Kollef M. Health Care-Associated Pneumonia and Community - Acquired Pneumonia: a Single-Center Experience. Antimicrobial Agents and Chemotherapy. 2007;51 (10): 3568-3573.

Falcone M, Venditti M, Shindo Y, Kollef M. Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. International Journal of Infectious Diseases. 2011;15 (8):e545-e550.

Venditti M. Outcomes of Patients Hospitalized with Community-Acquired, Health Care–Associated, and Hospital-Acquired Pneumonia. Annals of Internal Medicine. 2009;150(1):19.

YigitH, QueenanA, AndersonG, Domenech-Sanchez A, Biddle J, Steward C et al. Novel Carbapenem-Hydrolyzing -Lactamase, KPC-1, from a Carbapenem-ResistantStrain of Klebsiellapneumoniae. Antimicrobial Agents and Chemotherapy. 2001;45(4): 1151-1161.

Hossain A, Ferraro M, Pino R, Dew R, Moland E, Lockhart T et al. Plasmid-Mediated Carbapenem-Hydrolyzing Enzyme KPC-2 in an Enterobacter sp. Antimicrobial Agents and Chemotherapy. 2004;48(11): 4438-4440.

van Duin D, Doi Y. The global epidemiology of carbapenemase- producing Enterobacteriaceae. Virulence. 2016; 8(4):460-469.

Quale J, Landman D, Bradford P, Visalli M, Ravishankar J, Flores C et al. Molecular Epidemiology of a Citywide Outbreak of Extended‐Spectrum β‐Lactamase–ProducingKlebsiellapneumoniaeInfection. Clinical Infectious Diseases. 2002;35(7):834-841.

Kollef M, Shorr A, Tabak Y, Gupta V, Liu L, Johannes R. Epidemiology and Outcomes of Health-care–Associated Pneumonia. Chest. 2005;128(6):3854-3862.

Manikal V, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic Carbapenem-Resistant Acineto-bacter Species in Brooklyn, New York: Citywide Prevalence, Interinstitutional Spread, and Relation to Antibiotic Usage. Clinical Infectious Diseases. 2000;31 (1): 101-106.

Shrivastava S, Shrivastava P, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Journal of Medical Society. 2018;32(1):76.

Chalmers J, Taylor J, Singanayagam A, Fleming G, Akram A, Mandal P et al. Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care-Associated Pneumonia: A UK Cohort Study. Clinical Infectious Diseases. 2011;53(2):107-113.

Aliberti S, Di Pasquale M, Zanaboni A, Cosentini R, Brambilla A, Seghezzi S et al. Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming from the Community with Pneumonia. Clinical Infectious Diseases. 2011; 54 (4): 470-478.

Durlach R, McIlvenny G, Newcombe R, Reid G, Doherty L, Freuler C et al. Prevalence survey of healthcare-associated infections in Argentina; comparison with England, Wales, Northern Ireland and South Africa. Journal of Hospital Infection. 2012;80 (3) : 217-223.

Salgado Yepez E, Bovera M, Rosenthal V, González Flores H, Pazmiño L, Valencia F et al. Device-associated infection rates, mortality, length of stay and bacterial resistance in intensive care units in Ecuador: International Nosocomial Infection Control Consortium’s findings. World Journal of Biological Chemistry. 2017;8(1):95.

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). (2017). Kidney Inter-national Supplements, 7(1), pp.1-59.


  • There are currently no refbacks.